“A recently published randomized controlled trial found that the GLP-1 drug semaglutide substantially reduced alcohol consumption in heavy drinkers compared to a placebo,” reports The Doomslayer.
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.
Strongly significant reductions in drinking across measures. From the abstract: “Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder and this trial supports previous preclinical and clinical findings suggesting GLP-1 receptor agonists as a potential novel treatment target for alcohol use disorder.”
The Lancet explains:
Alcohol use disorder accounts for 5% of deaths worldwide annually, and there is an urgent need for new therapeutic interventions…. studies indicate that the GLP-1 receptor agonist semaglutide might reduce alcohol drinking. This study evaluated the efficacy of semaglutide once-weekly in treatment-seeking patients with alcohol use disorder and comorbid obesity.
Methods
In a 26-week, single-centre, randomised, double-blinded, placebo-controlled trial, treatment-seeking participants with moderate to severe alcohol use disorder and comorbid obesity were assigned (1:1) to receive once-weekly semaglutide (2·4 mg subcutaneously) or placebo (saline subcutaneously), in addition to standard cognitive behavioural therapy. The primary endpoint was a reduction in the number of heavy drinking days assessed after 26 weeks of intervention, analysed with an ANCOVA model….
Findings
From June 10, 2023, to Feb 4, 2025, 108 participants (53 women and 55 men) were enrolled, with 54 participants in each of the semaglutide and placebo treatment groups…Overall, 88 participants (81%) completed the full intervention. Semaglutide was associated with a reduction in heavy drinking days (–41·1 percentage points from baseline, 95% CI –48·7 to –33·5)…and had substantial effects on multiple secondary alcohol-related and somatic outcomes.
Obesity has finally stopped rising in America, thanks to anti-obesity drugs.
Fat acceptance and misinformation had fueled rising obesity rates. In 2021, Cosmopolitan magazine falsely suggested obesity is healthy. A fat-shaming “expert” went to work for San Francisco to normalize obesity.
